Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2026-05-22 Capital/Financing Update
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
NANOBIOTIX annonce l’exercice integral de l’option de surallocation, portant le produit de l'offre a 100 millions de dollars
Capital/Financing Update Classification · 90% confidence The document is a press release announcing Nanobiotix’s exercise of the over-allotment option in its global offering, raising total gross proceeds of $100 million. It details the issuance of additional ADS and ordinary shares, pricing, use of proceeds, and banks acting as bookrunners. This is a fundraising/capital transaction announcement rather than a full financial report or regulatory filing. Under our taxonomy, this fits “Capital/Financing Update” (CAP).
2026-05-22 French
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
Share Issue/Capital Change Classification · 93% confidence The document is a press release announcing the full exercise of the underwriters’ over-allotment option in a global offering of new ordinary shares in the form of ADSs, detailing the number of shares, offering price, use of proceeds, and related prospectus filing information. This is an equity financing transaction specific to a share issuance, not an earnings release or M&A, and it represents a capital change via new share issuance. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-05-22 English
NANOBIOTIX annonce les modalites definitives de son offre globale sursouscrite a hauteur de 85 millions d’euros
Capital/Financing Update Classification · 92% confidence The document is a press release announcing the definitive terms of Nanobiotix’s global offering of American Depositary Shares and pre-funded warrants, detailing pricing, quantities, overallotment option, use of proceeds, lock-up, and dilution effects. It clearly constitutes an update on a financing activity (capital raise), fitting the Capital/Financing Update category.
2026-05-21 French
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
Share Issue/Capital Change Classification · 87% confidence The document is a press release announcing the pricing and terms of an €85M global follow-on equity offering (ADSs, ordinary shares, and pre-funded warrants), detailing share issue amounts, pricing, underwriting arrangements, expected proceeds, lock-ups, and dilution. This is clearly an announcement of new share issuance (capital change). Such announcements fall under “Share Issue/Capital Change” (SHA).
2026-05-21 English
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
Capital/Financing Update Classification · 90% confidence The document is a corporate press release announcing the resumption of trading of ordinary shares following a previously announced public and international offering of ADSs, ordinary shares and pre-funded warrants. It provides details on the financing transaction and related capital market activity. This clearly falls under a capital/financing update rather than a full report or regulatory filing.
2026-05-21 English
Nanobiotix annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Capital/Financing Update Classification · 82% confidence The document is a dual-language press release announcing the resumption of trading of Nanobiotix shares on Euronext Paris following the completion of its global offering (public ADS offering in the U.S. and concurrent institutional share/warrant offering in Europe). It details the capital raising event and the related trading suspension and restart. This constitutes an update on the company’s financing activity, fitting the Capital/Financing Update category.
2026-05-21 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.